Sürdürülebilir Kalkınma Amaçları

Yazarlar

  • Derleme MakaleAçık Erişim2026
    Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges

    Koçak, Tevfik; Özbek, Yağmur Demirel; Bodur, Mahmut; Yeşil, Süleyman; Ağagündüz, Duygu

    Bladder cancer (BC) is a biologically heterogeneous tumor affected by genetic, metabolic, environmental, and lifestyle factors. Recent research indicates that nutrition can change the way urothelial cancer forms by affecting inflammation, oxidative stress, cellular energy, and the epigenome. It can also change the risk of BC and how well treatment works. Simultaneous progress in precision nutrition (PN) and nutriomic profiling—encompassing nutrigenomics, nutrigenetics, nutriepigenetics, metabolomics, and microbiome science—presents novel options to tailor dietary regimens beyond universal guidelines. In this review, we consolidate existing knowledge regarding the nutritional factors influencing BC, outline pertinent principles of PN for BC prevention and survival, and explore how urine proteomics and molecular subtyping facilitate the integration of PN into precision oncology. Our review examines the methodological, bioinformatic, biomarker, and clinical translation challenges that impede the implementation of PN in BC management; these challenges include the need for validated nutritional biomarkers with mechanistic endpoints, interoperable data platforms, and rigorously designed clinical trials. Finally, we emphasize future prospects for PN-guided medical nutrition therapy and dietary models during and after systemic treatment recovery. We propose research priorities that will facilitate the integration of PN-informed individualized dietary plans with medical and surgical approaches in BC treatment, aiming to decrease the costs associated with expensive or excessively aggressive treatment methods, thereby supporting long-term survival care. This review seeks to establish a conceptual framework for the integration of PN into BC management by delineating the opportunities and challenges, hence promoting hypothesis-driven research in a promising yet underexplored domain.

    • SDG 2 · Açlığa Son
    • SDG 3 · Sağlık ve Kaliteli Yaşam
  • MakaleAçık Erişim2021
    Urologists' Role and Attitude in the Systemic Treatment of Urologic Cancers

    Madendere, Serdar; Deger, Muslim Dogan; Demirkiran, Engin Denizhan; Yildiz, Huseyin Alperen

    Objective: The goal of this study was to investigate Turkish urologists' role and attitude toward the systemic treatment of urologic cancers. Materials and Methods: An 18-item survey was e-mailed to 2305 certified Turkish urologists. The survey included questions designed to evaluate urologists' knowledge of chemotherapy procedures and their ability to manage complications, as well as how many of them perform systemic therapies and believe urologists should perform these therapies for urologic cancers. Results: We evaluated 305 responses. Most urologists (89.6%) perform hormonotherapy for prostate cancers. Further, the majority refer patients to medical oncologists for chemotherapy. Moreover, 65.9%, 70.8%, and 72.1% of the urologists believe that only medical oncologists should deliver chemotherapy for prostate, bladder, and testicular cancers, respectively. Only 23.9% of urologists believe they are competent to perform chemotherapy, while 16.7% believe they are capable of dealing with chemotherapy complications. Conclusion: Turkish urologists have a lack of performance and interest in administering systemic therapies in urologic cancers. We want to emphasize that urology is more than just surgery. Urologists should be involved in all stages of cancer treatment.

    • SDG 3 · Sağlık ve Kaliteli Yaşam